Lipman G, Haidry R J
Department of Gastroenterology, University College Hospital NHS Foundation Trust, London, UK.
Division of Surgery & Interventional Science, University College London, London, UK.
Frontline Gastroenterol. 2017 Apr;8(2):138-142. doi: 10.1136/flgastro-2016-100763. Epub 2017 Feb 10.
Barrett's oesophagus (BO) is the only known precursor to oesophageal adenocarcinoma (OAC). Dysplasia and intramucosal cancer arising in BO can safely be treated with endoscopic eradication therapy (EET) due to the low risk of subsequent lymph node metastasis. Treatment at an early stage is paramount due to the ongoing poor prognosis and outcomes of patients with advanced OAC. The mainstay of treatment is endoscopic resection of visible lesions for accurate staging followed by ablation therapy to all remaining columnar-lined epithelium, most commonly with radiofrequency ablation. Successful eradication of dysplasia can be achieved in >95% of patients with this EET combined approach.
巴雷特食管（BO）是已知的食管腺癌（OAC）唯一前驱病变。由于后续淋巴结转移风险低，BO中出现的异型增生和黏膜内癌可通过内镜根除治疗（EET）安全治疗。鉴于晚期OAC患者的预后和结局持续不佳，早期治疗至关重要。治疗的主要方法是对可见病变进行内镜切除以准确分期，然后对所有剩余的柱状上皮进行消融治疗，最常用的是射频消融。采用这种EET联合方法，超过95%的患者可成功根除异型增生。
